CanWell Pharma Co., Ltd.

▲ 长按小程序码报名 2026柏思荟年会将于2026年9月10日-11日在上海浦东嘉里大酒店举办。年会以双品牌形式呈现——第八届生物药开发者创新大会（BDIC）和BIOSeedin Autumn Innovation Partnering Summit。研发与BD两大板块深度协同，挖掘前沿技术突破与商业合作潜力，助力创新价值从实验室走向全球市场。 我们诚邀更多全球生物医药企业、投资机构、创新团队加入。这个九月，在上海浦东嘉里大酒店，邀您共赴这场生物医药创新盛宴，以专业之力携手同行，共筑全球医药创新合作新未来！ 经过项目征集、资格初审及专家评审等多个环节的严格筛选，一批具备高成长性与技术壁垒的肿瘤项目脱颖而出。下面，我们一同走进这些优质企业，看看他们如何聚焦实际需求，带来专业、可行的创新解决方案。 肿瘤项目路演内容介绍 爱科瑞思 新型payload驱动ADC的发展 演讲人：苗振伟 爱科瑞思 董事长 由爱科瑞思自主研发的同类首创ADC新药ACR246靶向在肺癌、胃癌、胰腺癌、乳腺癌等高发难治实体瘤中高表达、在正常组织低表达的5T4靶点，精准治疗优势突出；产品依托全人源抗体、定点偶联稳定DAR=8、自研可裂解连接子、新型TOP1抑制剂载荷实现多项创新，凭借强旁观者效应破解实体瘤异质性难题，治疗窗口与耐受性优于传统微管抑制剂类ADC，临床前PDX模型抑瘤效果优异；该药2024年完成首次人体给药，经贝叶斯设计完成剂量爬坡后进入Ib/IIa扩展队列阶段，现有临床数据显示晚期实体瘤整体客观缓解率35%、疾病控制率80%，5T4阳性富集人群疾病控制率接近89%，不良反应可控且推荐二期剂量稳步确定，项目已落地全球权益授权合作，既是国产ADC工艺升级的优秀范例，也将为多线治疗失败的晚期实体瘤患者提供新方案，填补难治肿瘤靶向治疗缺口。 ACR246, a First-in-Class ADC independently developed by Adcori, targets the 5T4 biomarker highly expressed in prevalent refractory solid tumors including lung, gastric, pancreatic and breast cancers while showing minimal expression in healthy tissues, which grants it prominent precision therapy strengths. It integrates multiple technical innovations: a fully human antibody with site-specific conjugation maintaining a steady DAR of 8 for consistent batch quality, an in-house cleavable linker to reduce systemic off-target risks, and a novel TOP1 inhibitor payload with strong bystander effects to tackle tumor heterogeneity. It features a broader therapeutic window and better tolerability than conventional microtubule inhibitor-based ADCs, with potent antitumor efficacy validated in preclinical PDX models. First-in-human dosing was completed in 2024, followed by Bayesian-designed dose escalation to advance into the Ib/IIa expansion cohort. Published data record an overall ORR of 35% and DCR of 80% for advanced solid tumor patients, alongside a nearly 89% DCR for 5T4-positive subgroups; adverse events remain manageable and the recommended Phase II dose is being finalized. Having secured a global licensing deal, this candidate stands as a fine example of domestic ADC technological upgrades, delivers an innovative treatment option for heavily pretreated advanced solid tumor patients and is expected to fill the unmet need of targeted therapies for hard-to-treat malignancies. *项目简介可上下滑动查看 博锐创合 首创Nectin-4多肽诊疗一体化核药 ——从显像到治疗，精准赋能尿路上皮癌及更多瘤种 演讲人：单波 博锐创合 CEO 博锐创合是一家临床阶段的生物科技公司，致力于肿瘤精准诊疗一体化的创新型放射性药物开发，公司有4款产品处于临床开发阶段。BRP-020 是一款靶向细胞粘附蛋白 4（Nectin-4）的同类首创（First-in-Class）诊疗一体化药物。该药物采用环肽作为靶向配体，用于 Nectin-4 阳性实体瘤的诊断与治疗。临床前研究数据显示，BRP-020 具备优异的靶点亲和力与肿瘤靶向性，在肿瘤组织中表现出良好的滞留效应，同时在正常器官中快速清除，该药物展现出强劲的抗肿瘤活性和良好的安全耐受性。目前，BRP-020 处于研究者发起研究（IIT）阶段，公司正全力推进其 IND 开发工作。 BoomRay is a clinical-stage biotech pioneering innovative RLTs for the precise diagnosis and treatment of cancer, with four clinical-stage products currently in development. BRP-020 is a first-in-class, cyclic peptide-based radiopharmaceutical therapy (RLT) targeting Nectin-4 for the diagnosis and treatment of Nectin-4-expressing solid tumors. It demonstrates high binding affinity and specific tumor targeting, resulting in excellent tumor retention and rapid clearance from normal organs. These properties translate into robust anti-tumor activity and a favorable safety and tolerability profile. BRP-020 is currently under IIT development, with IND-enabling activities underway. *项目简介可上下滑动查看 多特生物 DB007 (PD-L1/TIGIT/IL-2 三特异性抗体)：通过独特的 IL-2“系留与激活”（Tether & Engage）机制，精准靶向肿瘤 CD8+ T 细胞 演讲人：Ignacio Asial 多特生物 联合创始人、CEO DB007 是由 DotBio 研发的一款处于临床前阶段的三特异性抗体，旨在治疗对现有免疫疗法产生耐药性（难治性）的癌症。 核心机制 •多靶点结合：同时靶向 PD-L1 和 TIGIT。 •“系留” IL-2（Tethered IL-2）：携带独特的专利“非活性”白介素-2（IL-2）片段。它在全身血液循环中保持关闭状态，只有在肿瘤微环境中精准锚定靶点后才会被激活，从而安全地唤醒耗竭的 CD8+ T 细胞，避免全身性毒副作用。 主要优势 •高安全性：在临床前模型中未出现死亡案例，且系统性 T 细胞扩增受控（相比之下，竞品如 IBI-363 具有高毒性并导致高死亡率）。 •疗效显著：在动物模型中的抑瘤效果优于 Keytruda（帕博利珠单抗），并使肿瘤内部的活性 T 细胞显著增加 56%。 •易于生产：基于高稳定性的 “DotBody” 人源单域抗体平台开发，细胞株表达量高达 5–10 g/L，极具商业化量产优势。 当前进展 •DB007 目前处于 IND（临床试验申报）准备阶段。DotBio 正在进行 2000 万美元的 A 轮融资，以推动该项目进入 I 期临床试验。 DB007 is a preclinical-stage, tri-specific antibody developed by DotBio to treat immuno-oncology refractory cancers. How It Works •Targeting: Simultaneously binds PD-L1 and TIGIT. •Tethered IL-2: Features a proprietary "dead" IL-2 (interleukin-2) tether. It remains inactive in blood circulation but reactivates exhausted CD8+ T-cells once anchored to the tumor microenvironment, preventing off-target side effects. Key Advantages •High Safety: Zero deaths and controlled immune expansion in preclinical models (unlike competitors like IBI-363, which showed high toxicity). •Strong Efficacy: Outperformed Keytruda in animal models, driving a 56% increase of active T-cells inside tumors. •Easy to Manufacture: Built on stable "DotBody" human domain scaffolds, achieving high production yields of 5–10 g/L. Current Status •DB007 is in the IND-enabling phase. DotBio is currently raising a $20 million Series A round to advance the candidate into Phase I clinical trials *项目简介可上下滑动查看 健士拜生物 GS003，新型多重机制抗PD-L1/B7H3双特异性ADC项目介绍 演讲人：林军 健士拜生物 总经理 GS003是一款潜在同类最佳、高度差异化、拥有多重作用机制的PD-L1/B7H3 ADC（DAR 8）。设计上，该分子PD-1/PD-L1阻断功能保留，内吞优于亲本单抗及竞品，同时使用亲水性增强连接子，载荷相对于DXd拥有更强的旁观者效应并可克服多药耐药。体外、体内模型均显示强效抗肿瘤活性，超越竞品。双抗ADC的PK特性良好，载荷提前释放极少；食蟹猴探索性毒理显示在≥30mg/kg剂量下耐受良好。GS003的生物物理性质优异，对于CMC开发有利。这些特性使GS003成为竞争优势显著的新一代双抗ADC。 GS003 is a potential best-in-class, highly differentiated PD-L1/B7H3 ADC. Its differentiated design includes better endocytosis than parent mAbs, a hydrophilicity-enhanced linker, and an improved payload over DXd, featuring stronger bystander killing and the ability to overcome multi-drug resistance. GS003 demonstrates robust anti-tumor activity in multiple in vitro and in vivo models, outperforming competitors. It has favorable PK with minimal premature payload release, and an acceptable safety profile (well tolerated at ≥30 mg/kg in cynomolgus monkeys). Excellent biophysical properties support robust CMC development. These attributes position GS003 as a next-generation ADC with compelling competitive advantages. *项目简介可上下滑动查看 康威生物 多载荷 ADC StarLinker 技术平台 演讲人：余宁辉 康威生物 总裁兼CEO 针对传统单载荷ADC在肿瘤异质性和耐药机制下的疗效瓶颈，康威生物创新打造了 StarLinker 多载荷偶联技术平台。StarLinker先将载荷与连接子高纯度合成（LP），再以单步偶联反应将双/多载荷按不同比例（如1:1、2:1、1:1:1等）连接至非工程化天然抗体，不依赖酶促反应，工艺简洁、批间均一性高。基于该平台，康威生物已系性统验证了多种不同机制的双载荷连接子组合，布局了的多款不同靶点的双载荷ADC候选管线，已相继进入PCC、IND-Enabling或临床试验阶段。 其中，CAN016是基于starlinker平台，首款获批临床试验的Her2--双毒素抗体偶联药物，目前正在开展I期临床研究，将评估CAN016的安全性、耐受性及药代动力学特征，确定后续临床开发的推荐剂量，并探索其在经ADC治疗的实体瘤中的初步抗肿瘤疗效。临床前研究显示，CAN016通过在肿瘤细胞内释放出两种细胞毒性载荷，具有显著的协同增效作用，最终强效抑制肿瘤细胞的增殖并诱导其凋亡，对包括Enhertu（DS8201）耐药在内的CDX和PDX肿瘤模型均展现出优异的肿瘤杀伤效果。 To overcome the inherent limitations of single-payload ADCs--tumor heterogeneity and resistance--CanWell has pioneered the StarLinker multi-payload conjugation platform. StarLinker enables the high-purity synthesis of linker-payloads (LP) prior to conjugation. Through a single-step reaction, it facilitates the precise, ratio-controlled loading of dual or multiple payloads (e.g., 1:1, 2:1, 1:1:1) onto native, non-engineered antibodies—entirely independent of enzymatic catalysis. This streamlined process ensures high batch-to-batch consistency. Leveraging this platform, CanWell has systematically validated various dual-payload linker combinations with distinct mechanisms of action (MoA) and built a robust pipeline of dual-payload ADC candidates targeting diverse antigens, which are advancing through PCC, IND-enabling studies, and clinical development stage. CAN016, the first HER2-targeted dual-payload ADC derived from the StarLinker platform to enter clinical trials, is currently in Phase I. The study will evaluate the safety, tolerability, and pharmacokinetics of CAN016, determine the RP2D, and explore its preliminary antitumor efficacy in patients with solid tumors previously treated with ADCs. Preclinical studies demonstrate that CAN016 exerts significant synergistic effects by releasing two distinct cytotoxic payloads inside tumor cells, leading to potent inhibition of proliferation and induction of apoptosis. It has exhibited robust tumor-killing activity across multiple CDX and PDX models, including those refractory to Enhertu (DS-8201). *项目简介可上下滑动查看 星联肽生物 差异化的抗肿瘤多肽偶联PDC药物开发 演讲人：程萍 星联肽生物 商务副总裁 星联肽SC-101是靶向NECTIN-4的PDC药物，正在开展乳腺癌、尿路上皮癌、头颈癌的临床研究1b/2a期，研发进展处于全球第二、国内第一的地位。根据已经完成的临床1a期试验，在未经MMAE治疗的尿路上皮癌患者中，展示出80%的ORR和100% DCR的数据。与同靶点的ADC药物（PADCEV）或PDC（BT8009）相比，SC-101在机制、安全性、临床效果上，都展现出了明确的差异化优势。预计在2026年3季度，将展示出在乳腺癌、头颈癌等其他实体瘤的2期临床试验数据。 SC-101 is currently in Phase 1b/2a dose expansion in TNBC and HNC patients. In the dose escalation study in UC patients (MMAE naivee), SC-101 demonstrated a 100% DCR and an 80% ORR. These results that significantly exceed the clinical outcomes observed with Nectin-4 ADC (Padcev) and our competitor programs, including Bicycle Therapeutics’ Nectin-4-targeted candidate. In addition, we will share the confirmation of our RP2D and initial dose expansion study data in non-UC solid tumors (TNBC, Head and neck cancers) in 2026Q3 . *项目简介可上下滑动查看 微可蔚生物 新一代溶瘤病毒免疫疗法——引领复发胶质母细胞瘤治疗新纪元 演讲人：张熠丹 微可蔚生物 CEO 微可蔚生物（VacV Biotherapeutics）是一家处于临床阶段的生物技术公司，专注开发新一代基因工程溶瘤病毒免疫疗法。公司核心管线 BioTTT001 在多种中枢神经系统恶性肿瘤中展现出可观的临床疗效；静脉给药痘苗病毒技术平台（VacV00X）则可拓展用于更多实体瘤，涵盖转移性胰腺导管腺癌、结直肠癌、非小细胞肺癌、去势抵抗性前列腺癌等。公司采用英‑中‑美三地一体化运营模式，兼顾早期研发的高效推进与全球注册申报布局。 VacV Biotherapeutics is a clinical-stage biotech company developing next-generation genetically engineered oncolytic virus immunotherapy. Our lead program, BioTTT001, has shown encouraging clinical activity in multiple types of CNS malignancies, while our IV-deliverable vaccinia platform (VacV00X) expands into broader solid tumors including metastatic PDAC, CRC, NSCLC, CRPC, etc. We operate a UK-China–US integrated model, combining rapid early development with global registrational strategy. *项目简介可上下滑动查看 拿因生物 靶向整合应激反应通路克服肿瘤耐药的新药研发 演讲人：王英杰 拿因生物 创始人 整合应激反应（ISR）是肿瘤细胞应对内质网应激、营养匮乏、氧化应激和致癌压力等多种压力的关键适应性机制，通过eIF2α磷酸化、ATF4转录重编程等通路，在维持肿瘤细胞存活、促进肿瘤生长、转移及耐药中发挥双重作用。当上列胞内外压力在一定范围内时，肿瘤细胞可通过激活ISR通路，启动适应性调节机制来促进肿瘤存活和增殖，由此导致复发耐药和肿瘤转移；当压力超出可适应范围后，过分激活的ISR会引发肿瘤细胞凋亡等调节性细胞死亡。针对ISR的双重性特征，拿因生物研发了NAI003D和NAI005，分别通过过分激活和抑制ISR通路，诱导肿瘤细胞死亡和增殖受阻，在体外培养的耐药肿瘤细胞、病人来源的原代肿瘤细胞（PDC）、小鼠体内CDX和PDX等模型中都展现出优异的抗肿瘤活性。 The Integrated Stress Response (ISR) is a key adaptive mechanism for cancer cells to cope with a variety of stresses including endoplasmic reticulum stress, nutrient deprivation, oxidative stress and oncogenic stress. Through pathways such as eIF2α phosphorylation and ATF4 transcriptional reprogramming, it plays dual roles in maintaining cancer cell survival and promoting cancer growth, metastasis and drug resistance. When the above intracellular and extracellular stresses are within a certain range, cancer cells can activate the ISR pathway to initiate adaptive regulatory mechanisms to promote their survival and proliferation, which further leads to cancer recurrence, drug resistance and metastasis; when the stress exceeds the adaptive range, the overactivated ISR will trigger regulated cell death such as apoptosis in cancer cells. Aiming at the dual characteristics of ISR, Nain Biotech has developed NAI003D and NAI005, which can induce regulated cell death and block the proliferation of cancer cells by overactivating and inhibiting the ISR pathway, respectively. Both candidates have demonstrated excellent anti-cancer efficacy in in vitro cultured drug-resistant cancer cells, patient-derived primary cancer cells (PDC), in vivo CDX and PDX mouse models. *项目简介可上下滑动查看 希格生科 “类器官+AI”平台赋能全球首个弥漫性胃癌FAK/SRC双靶点抑制剂的研发 演讲人：戴雪希 希格生科 业务拓展总监 SIGX1094R是全球首个针对弥漫性胃癌的靶向药、首个FAK/SRC双靶点抑制剂，也是首个由“类器官+AI”平台驱动的创新药物，已获FDA孤儿药及快速通道资格。在胃癌类器官及PDX模型中，其抗肿瘤活性为同类竞品的10倍以上。单药对卵巢癌、三阴性乳腺癌、胰腺癌均有效；作为平台型分子，联合KRAS和EGFR抑制剂可显著增强抗肿瘤药效并克服耐药。其腹腔微球制剂在癌性腹水治疗中潜力巨大。目前处于临床I期，预计下半年进入II期。 SIGX1094R is the world's first targeted therapy for DGC, the first FAK/SRC dual-target inhibitor, and the first innovative drug discovered through an "Organoid+AI" platform. It has received FDA Orphan Drug Designation and Fast Track designation. In gastric cancer organoid and PDX models, its antitumor activity is more than 10 times greater than that of competing agents. As a monotherapy, it is effective against ovarian cancer, triple-negative breast cancer, and pancreatic cancer. As a platform molecule, it combines with KRAS and EGFR inhibitors to significantly enhance antitumor efficacy and overcome drug resistance. Its unique intraperitoneal microsphere formulation also holds great potential for treating malignant ascites. Currently in Phase I clinical development, it is expected to advance to Phase II in the second half of the year. *项目简介可上下滑动查看 以上路演企业均已录入大会1-on-1洽谈系统，与会嘉宾可通过系统提前预约，与心仪企业创始人及核心团队进行面对面深度交流，精准对接合作需求。 路演企业公布 除肿瘤创新项目外，本次专场还汇聚了以下多元赛道的优秀企业，涉及自身免疫性疾病、眼科、心血管及肾脏代谢、中枢神经系统（CNS） 等领域 参会路演企业名单： MNC/买家 阵容公布 多家跨国药企（MNC）均开设专属1-on-1会议室，各TA负责人将进驻线上1-on-1约见系统。biotech公司可根据自身管线需求，提前预约MNC的洽谈席位，届时在专属会议室与对方决策层面对面深度交流，高效推动合作意向。 议程框架 ▸ BIOSeedin Autumn Innovation Partnering Summit 设自免、代谢、肿瘤、CNS、眼科、综合其他、临床出海（丹麦专场）路演，配套圆桌讨论及1-on-1精准对接系统。面向企业决策者、BD负责人、投资人，推动项目落地与跨境交易。 ▸ 第八届生物药开发者创新大会（BDIC） 聚焦早研技术，设【抗体早研】、【新药热点与前沿】、【细胞治疗产业化之路】三大主题，12个分论坛。深度覆盖药物创新全流程的技术突破与产业化实践。不设致辞与主论坛环节，开门见山，每一场分享皆为技术干货。 观众报名 免费论坛票：仅限药企、科研院所、投资机构从业人员（需提交工作证明/名片审核），不含餐。 付费论坛票：其他参会人员（如CRO、CDMO、试剂仪器、律所、咨询公司等服务机构），含自助午餐。 1- on -1对接票：面向药企、科研院所、投资机构开放，每家公司限2人，先报名先得（需通过审核，名额有限）。 具体费用及审核标准，请参见官网及小程序内详情页。 注：免费票需经组委会审核通过后生效，名额有限，建议尽早报名。 大会组织框架 更多企业持续确认中…… 合作联系 路演申请： Lexy 13335713260（同微信） 赞助合作： 陈先生 19157878651（同微信） 参会咨询： 焦女士 19946296879 （同微信） amanda 15867156922（同微信） 1-on-1咨询： Alice 17816049832（同微信） 或发送邮件至：service@bioseedin.com ▲点击图片跳转报名

SAN DIEGO 圣地亚哥, ，July 13, 2026 2026年7月13日/PRNewswire/ -- Ahead of the BIO International Convention,BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stage clinical pipelines, business development strategies, M&A trends, multinational collaboration models, and global licensing transactions.. /美通社/ -- 在BIO国际大会召开前夕，bioSeedin夏季创新合作峰会于加利福尼亚州圣地亚哥湾畔温德姆酒店成功举办。本次峰会由bioSeedin主办，讨论议题涵盖早期创新资产、后期临床管线、业务发展策略、并购趋势、跨国合作模式以及全球许可交易。Continue Reading 继续阅读Liveshots at the BIOSeedin Summer Innovation Partnering Summit BIOSeedin夏季创新合作峰会现场直播ACROBiosystems participated as a key strategic partner under the theme 'Enabling Global Opportunity,' working with a broad network of industry partners to build a strategic partnering platform for the globalization of innovation assets. The event gathered more than 200 participants from over 30 countries, creating a highly active environment for business dialogue and partnering discussions.. ACROBiosystems以“赋能全球机遇”为主题，作为关键战略合作伙伴参会，与广泛的行业合作伙伴网络携手，打造创新资产全球化的战略合作平台。本次活动吸引了来自30多个国家的200多位参与者，营造了极为活跃的商业对话与合作洽谈氛围。During the summit, ACROBiosystems set up a dedicated networking lounge to provide attendees with an exclusive space for in-depth discussion, helping turn thought leadership and ideas into tangible collaboration. 峰会期间，ACROBiosystems设立了专属的交流酒廊，为与会者提供进行深入探讨的私密空间，助力将思想领导力与创意转化为实质性的合作。As innovative drug development becomes increasingly global, ACROBiosystems is further leveraging its global customer network, technical service capabilities, industry insight, and ecosystem connectivity to advance its role as a global strategic partner for innovation. Through the summit, ACROBiosystems aims to amplify the visibility of high-potential innovation assets and help them gain greater international recognition, deeper industry understanding, and more partnering opportunities during a critical window for the global biopharmaceutical industry.. 随着创新药研发日益全球化，ACROBiosystems（义翘科技）正进一步 leveraging 其全球客户网络、技术服务能力、行业洞察力以及生态系统连接性，以强化其作为全球创新战略合作伙伴的角色。通过本次峰会，ACROBiosystems 旨在提升高潜力创新资产的可见度，帮助它们在全球生物医药行业的关键窗口期获得更广泛的国际认可、更深入的行业理解以及更多的合作机会。From winter to summer, ACROBiosystems has continued to advance global innovation partnerships. Following the BIOSeedin Winter Innovation Partnering Summit in San Francisco this January and the BIOSeedin Spring Innovation Partnering Summit in Shanghai this May, the BIOSeedin Summer Innovation Partnering Summit in San Diego further extended this momentum. 从冬季到夏季，义翘科技（ACROBiosystems）持续推动全球创新合作伙伴关系的发展。继今年一月在旧金山举办的BIOSeedin冬季创新合作峰会以及今年五月在上海举办的BIOSeedin春季创新合作峰会之后，于圣地亚哥举行的BIOSeedin夏季创新合作峰会进一步延续了这一势头。Besides, ACROBiosystems has also hosted ACRO Innovation Day and the ACRO Innovation Forum in Europe and Shanghai, reinforcing its commitment to empowering the industry and building platforms for innovation exchange.. 此外，ACROBiosystems还在欧洲和上海举办了ACRO创新日和ACRO创新论坛，进一步强化了其赋能行业、搭建创新交流平台的承诺。Looking ahead, ACROBiosystems will continue to work with global partners around its core brand values of 'Reliable Quality, Integrated Innovation, and Considerate Service', jointly accelerating the translation of biopharmaceutical innovation into clinical applications and global markets. 展望未来，ACROBiosystems将继续围绕“可靠的质量、集成创新和周到服务”的核心品牌价值，与全球合作伙伴携手，共同加速生物制药创新向临床应用和全球市场的转化。Summit Recap 峰会回顾The summit opened with remarks from Ms. Jenny Zhao, Co-founder and CEO of bioSeedin. 峰会以 bioSeedin 联合创始人兼首席执行官赵珍妮女士的致辞开幕。And then the summit went on with panels and company presentations, along with one on one partnering session to motivate exchange and precision collaborations. 随后，峰会继续进行小组讨论和企业推介，并安排了一对一洽谈环节，以促进交流与精准合作。The panel session split into two parts: the early-stage and late-stage session. 小组讨论环节分为两部分：前期阶段和后期阶段。No. 1 Early-Stage Session 第一期 早期阶段会议The Early-Stage Session featured two panel discussions on licensing, external innovation, and M&A. The first panel brought together executives from Debiopharm, Otsuka Pharmaceutical, Roche/Genentech, AstraZeneca. 早期阶段会议设有两场关于许可、外部创新及并购的小组讨论。第一场小组讨论汇聚了来自德彪制药、大冢制药、罗氏/基因泰克和阿斯利康的高管。Key Takeaways: 核心要点：Licensing is not simply an asset transaction, but a strategic tool for translating differentiated science into long-term value. 许可并非单纯的资产交易，而是将差异化科学成果转化为长期价值的战略工具。Strong biology, high-quality data, translational continuity, and a credible global clinical development plan remain essential to deal execution. 强大的生物学基础、高质量的数据、转化连续性以及可信的全球临床开发计划，对于达成交易仍然至关重要。Deals often stall due to weak biological rationale, unclear patient or biomarker strategies, poor PK/PD or therapeutic windows, and inadequate global development planning. 交易常常因生物学依据不足、患者或生物标志物策略不明确、药代动力学/药效学（PK/PD）或治疗窗不佳，以及全球开发计划不充分而停滞。The second panel was moderated by Kenneth C. Chen, Senior Director of Business Development, US & EU, at bioSeedin, and featured executives from Sun Pharma, Hygieia Pharma, and Servier. 第二场小组讨论由bioSeedin公司美欧业务发展高级总监Kenneth C. Chen主持，来自Sun Pharma、Hygieia Pharma和Servier的高管参与了讨论。Key Takeaways: 核心要点：M&A should support long-term corporate strategy rather than serve as an end goal. 并购应支持企业的长期战略，而不应成为最终目标。Companies need to balance acquisitions, strategic investments, and licensing transactions. 企业需要平衡并购、战略投资和许可交易。Successful M&A depends on valuation discipline, rigorous due diligence, effective execution, and post-deal integration. 成功的并购取决于估值纪律、严格的尽职调查、有效的执行以及交易后的整合。The session also included company presentations from Antengene, GeneScience Pharmaceutical, and Salsola Therapeutics, showcasing innovative pipelines across autoimmune diseases, immunology, and neuropsychiatric disorders. 会议还包括来自Antengene、GeneScience Pharmaceutical和Salsola Therapeutics的公司介绍，展示了在自身免疫性疾病、免疫学和神经精神疾病领域的创新研发管线。No. 2 Late-Stage Session 第二场 后期阶段会议The Late-Stage Session Executives from Daiichi Sankyo, Takeda, Boehringer Ingelheim, and Thermo Fisher Scientific discussed the global innovation ecosystem and emerging industry trends. 来自第一三共、武田制药、勃林格殷格翰和赛默飞世尔科技的后期阶段会议高管讨论了全球创新生态系统和新兴行业趋势。Key Takeaways: 核心要点：Innovation must remain grounded in strong science, robust biology, high-quality data, and rigorous R&D. 创新必须始终立足于坚实的科学基础、可靠的生物学依据、高质量的数据以及严谨的研发工作。China and AI are long-term structural forces rather than short-term trends. Companies need a clear and coherent China strategy. 中国与人工智能是长期的结构性力量，而非短期趋势。企业需要制定清晰且连贯的中国战略。AI can support the full R&D value chain, but it cannot replace scientific fundamentals. 人工智能可以支持整个研发价值链，但无法取代科学基础。The session also featured presentations from HighTide Therapeutics, Constimulus Bio, CanWell Pharma, Jiangsu Chia Tai Fenghai Pharmaceutical, Amphiprotech, and VyBio, showcasing advanced pipelines and global development opportunities across multiple therapeutic areas. 会议还展示了来自HighTide Therapeutics、Constimulus Bio、CanWell Pharma、江苏正大丰海制药有限公司、Amphiprotech和VyBio的报告，呈现了多个治疗领域的先进研发管线和全球开发机会。About ACROBiosystems Group: 关于ACROBiosystems集团：ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. 义翘科技集团成立于2010年，于2021年上市，是一家生物技术公司，旨在通过提供创新产品和商业模式，成为全球生物医药和医疗健康产业的基石。公司业务遍布全球，在美国、瑞士、英国和德国的15多个城市设有办事处、研发中心和生产基地。ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as. ACROBiosystems集团已与包括辉瑞、诺华和强生在内的全球顶尖制药企业以及众多知名学术机构建立了众多长期稳定的合作伙伴关系。该公司旗下拥有多家子公司，例如。A ACROBiosystems, CROBiosystems，b bioSeedin, ioSeedinC Condense Capital, and ACRO On dense Capital 和 ACROD Diagnostics. 诊断。ACROBiosystems' brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. ACROBiosystems旗下的品牌包括Resilient Supply、CytoPak、SAFENSURE、FLAG、Star Staining、Aneuro、ComboX、GENPower等众多品牌。其主要产品和服务包括重组蛋白、试剂盒、抗体、科学服务及其他相关产品。ACROBiosystems对其产品实施严格的质量控制体系，这些产品广泛应用于生物制药的研发、生产及临床应用。This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.. 这包括靶向发现与验证、候选药物筛选/优化、CMC开发与中试生产、临床前研究、临床试验、商业化生产以及伴随诊断的临床应用。Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.. 通过持续开发新技术和新产品，ACROBiosystems集团为全球制药行业创造价值，并积极赋能合作伙伴。公司致力于加速药物研发进程，涵盖靶向疗法、免疫治疗药物及其临床应用，为全球健康事业贡献力量。SOURCE ACROBiosystems 来源：ACROBiosystems21 二十一% %more press release views with 更多新闻稿浏览量，借助Request a Demo 申请演示

SAN DIEGO, July 13, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stage clinical pipelines, business development strategies, M&A trends, multinational collaboration models, and global licensing transactions. Continue Reading Liveshots at the BIOSeedin Summer Innovation Partnering Summit ACROBiosystems participated as a key strategic partner under the theme "Enabling Global Opportunity," working with a broad network of industry partners to build a strategic partnering platform for the globalization of innovation assets. The event gathered more than 200 participants from over 30 countries, creating a highly active environment for business dialogue and partnering discussions. During the summit, ACROBiosystems set up a dedicated networking lounge to provide attendees with an exclusive space for in-depth discussion, helping turn thought leadership and ideas into tangible collaboration. As innovative drug development becomes increasingly global, ACROBiosystems is further leveraging its global customer network, technical service capabilities, industry insight, and ecosystem connectivity to advance its role as a global strategic partner for innovation. Through the summit, ACROBiosystems aims to amplify the visibility of high-potential innovation assets and help them gain greater international recognition, deeper industry understanding, and more partnering opportunities during a critical window for the global biopharmaceutical industry. From winter to summer, ACROBiosystems has continued to advance global innovation partnerships. Following the BIOSeedin Winter Innovation Partnering Summit in San Francisco this January and the BIOSeedin Spring Innovation Partnering Summit in Shanghai this May, the BIOSeedin Summer Innovation Partnering Summit in San Diego further extended this momentum. Besides, ACROBiosystems has also hosted ACRO Innovation Day and the ACRO Innovation Forum in Europe and Shanghai, reinforcing its commitment to empowering the industry and building platforms for innovation exchange. Looking ahead, ACROBiosystems will continue to work with global partners around its core brand values of "Reliable Quality, Integrated Innovation, and Considerate Service", jointly accelerating the translation of biopharmaceutical innovation into clinical applications and global markets. Summit Recap The summit opened with remarks from Ms. Jenny Zhao, Co-founder and CEO of bioSeedin. And then the summit went on with panels and company presentations, along with one on one partnering session to motivate exchange and precision collaborations. The panel session split into two parts: the early-stage and late-stage session. No. 1 Early-Stage Session The Early-Stage Session featured two panel discussions on licensing, external innovation, and M&A. The first panel brought together executives from Debiopharm, Otsuka Pharmaceutical, Roche/Genentech, AstraZeneca. Key Takeaways: Licensing is not simply an asset transaction, but a strategic tool for translating differentiated science into long-term value. Strong biology, high-quality data, translational continuity, and a credible global clinical development plan remain essential to deal execution. Deals often stall due to weak biological rationale, unclear patient or biomarker strategies, poor PK/PD or therapeutic windows, and inadequate global development planning. The second panel was moderated by Kenneth C. Chen, Senior Director of Business Development, US & EU, at bioSeedin, and featured executives from Sun Pharma, Hygieia Pharma, and Servier. Key Takeaways: M&A should support long-term corporate strategy rather than serve as an end goal. Companies need to balance acquisitions, strategic investments, and licensing transactions. Successful M&A depends on valuation discipline, rigorous due diligence, effective execution, and post-deal integration. The session also included company presentations from Antengene, GeneScience Pharmaceutical, and Salsola Therapeutics, showcasing innovative pipelines across autoimmune diseases, immunology, and neuropsychiatric disorders. No. 2 Late-Stage Session The Late-Stage Session Executives from Daiichi Sankyo, Takeda, Boehringer Ingelheim, and Thermo Fisher Scientific discussed the global innovation ecosystem and emerging industry trends. Key Takeaways: Innovation must remain grounded in strong science, robust biology, high-quality data, and rigorous R&D. China and AI are long-term structural forces rather than short-term trends. Companies need a clear and coherent China strategy. AI can support the full R&D value chain, but it cannot replace scientific fundamentals. The session also featured presentations from HighTide Therapeutics, Constimulus Bio, CanWell Pharma, Jiangsu Chia Tai Fenghai Pharmaceutical, Amphiprotech, and VyBio, showcasing advanced pipelines and global development opportunities across multiple therapeutic areas. About ACROBiosystems Group: ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRO Diagnostics. ACROBiosystems' brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health. SOURCE ACROBiosystems 21% more press release views with Request a Demo